Table 1. Cross-comparison of major CF subpopulations in healthy and diseased mouse hearts.
Fibroblast abbreviations—Farbehi et al. study (9): F-SH, Fibroblast-Sca1high; F-SL, Fibroblast-Sca1low; F-Trans, Fibroblast-transitory; F-IFNS, Fibroblast-interferon stimulated; F-WntX, Fibroblast-Wnt expressing; F-Act, Fibroblast-activated; F-CI, Fibroblast-cycling intermediate; F-Cyc, Fibroblast cycling; MYO, myofibroblast. Fibroblast abbreviations—Forte et al. study (10): PLS, progenitor-like state fibroblast; HEpiD, homeostatic epicardial-derived fibroblasts; IFNr, interferon response; EndD, endocardial-derived fibroblasts; LR, late-resolution fibroblasts; IR, IR fibroblasts; ProlifMyofb, proliferating myofibroblasts; Myofb, myofibroblasts; MFC, matrifibrocytes. Other abbreviations: aCSC, activated cardiac stromal cells; AngII, AngII-induced heart failure model; CSC, cardiac stromal cells; ns, not specified; RCF, reparative CF.
| Study | Farbehi et al. (9) | Forte et al. (10) | Janbandhu et al. (8) | Ruiz-Villalba et al. (28) | Hesse et al. (62) | McLellan et al. (63) | Alexanian et al. (51) | |
|---|---|---|---|---|---|---|---|---|
| Model | Sham + MI* | Uninjured + MI† | Uninjured + sham + MI‡ | Uninjured + MI§ | Sham + IRI | Untreated + Saline + AngII | Sham + TAC | |
| CF enrichment | Pdgfra-GFP+ | In silico from nonmyocytes | Pdgfra-lineage+CD31−CD45−− | Col1a1-GFP+ | In silico from CD31−CD45− nonmyocytes | In silico from myocytes and nonmyocytes | In silico from nonmyocyte | |
| After injury days | 3, 7 | 1, 3, 5, 7, 14, 28 | 3 | 7, 14, 30 | 5 | 14 | 62 | |
| Total cells integrated | 16,375 | 19,339 | 8504 | 13,950 | 26,828 | 14,046 | 9477 | |
| Male/female | Male | Male and female | Male | ns | Male | Male and female | ns | |
| Strain | C57Bl/6J | C57Bl/6J | C57Bl/6J | C3H/C57B1¶ | C57Bl/6J | C57Bl/6J | ns | |
| Top enriched markers ** | ||||||||
| Populations | F-SH | PLS# | F-SH | Cluster D# | CSC-4 and aCSC-4# | Fibroblast-6# | ns# | Ly6c1;Pi16;Ly6a(Sca1);Cd248;Gfpt2 |
| F-SL | HEpiD | F-SL | Cluster A/C | CSC-1 and CSC-2 | ns | ns | Cxcl14;Hsd11b1;Lpl;Dpep1;G0s2 | |
| F-Trans | ns | F-Trans | Cluster H | CSC-5 | Fibroblast-2 | ns | Igfbp3;Apoe;Ccl19;Fgl2;Inmt | |
| F-IFNS | IFNr | F-IFNS | Cluster I | CSC-9 and aCSC-8 | Fibroblast-9 | ns | Ifit3;Isg15;Ifit1;Cxcl10;Ligp1 | |
| F-WntX | EndD | F-WntX | Cluster H | CSC-11 and aCSC-11 | Fibroblast-Wif1 | ns | Wif1;Prg4;Dkk3; Cytl1;Clu | |
| F-Act | LR | F-Act | Cluster F | CSC-3 | Fibroblast-Clip | ns | Meox1;Cst6;Col8a1;Cilp;Ckb | |
| F-CI | ns | F-CI | ns | ns | ns | ns | Timp1;Spp1;Acta2;Cxcl5;Tmp2 | |
| ns | IR | ns | ns | ns | ns | ns | Mt2;Ccl2;Timp1;Cxcl5;Angptl4 | |
| F-Cyc | ProlifMyofb | F-Cyc | ns | aCSC-7 and aCSC-10 | ns | ns | Stmn1;Cks2;H2afz;Cenpa;Hmgb2 | |
| MYO | Myofb | ns | Cluster B (RCF) | aCSC-1, aCSC-2, and aCSC-3 | Absent | ns | MYO: Cthrc1;Fn1,Ptn;Col1a1;Acta2 | |
| MYO-1 | ns | ns | ns | ns | ns | MYO-1: Wisp2;Sfrp2;Sfrp1,Ccn5,Fbln1 | ||
| MYO-2 | ns | ns | ns | ns | ns | MYO-2: Tgfb1;Thbs4;Crlf1,Col15a1 | ||
| ns | MFC | ns | Cluster B (RCF) day 14/30 | ns | Fibroblast-Thbs4 | ns | Comp;Sfrp2;Ecrg4;Angptl7;Eln |
*Uninjured and MI mice were on a heterozygous PdgfraGFP background.
†Uninjured and MI mice were on a TgWt1IRES-EGFP-Cre;RosaZsGreenf/+ background.
‡Uninjured, sham and MI mice were on conditional (PdgframerCRE-mer) heterozygous Hif1a knockout background.
§Uninjured and MI mice were on a TgCol1a1GFP background.
¶Transgene background strain not specified in the Ruiz-Villalba et al. study (28); original background cited as C3H/C57B1.
#CF sub-populations were inferred by comparison with reported marker gene lists where available.
**Top 5 enriched markers taken from integrated data (see Fig. 1F and table S1). See text for MYO-1 and MYO-2 markers.